BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10485454)

  • 1. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.
    Yu DC; Chen Y; Seng M; Dilley J; Henderson DR
    Cancer Res; 1999 Sep; 59(17):4200-3. PubMed ID: 10485454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
    Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
    Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.
    Yu DC; Sakamoto GT; Henderson DR
    Cancer Res; 1999 Apr; 59(7):1498-504. PubMed ID: 10197620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
    Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
    Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.
    Rodriguez R; Schuur ER; Lim HY; Henderson GA; Simons JW; Henderson DR
    Cancer Res; 1997 Jul; 57(13):2559-63. PubMed ID: 9205053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer.
    Lee SJ; Zhang Y; Lee SD; Jung C; Li X; Kim HS; Bae KH; Jeng MH; Kao C; Gardner T
    Mol Ther; 2004 Dec; 10(6):1051-8. PubMed ID: 15564137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy.
    Cowen D; Salem N; Ashoori F; Meyn R; Meistrich ML; Roth JA; Pollack A
    Clin Cancer Res; 2000 Nov; 6(11):4402-8. PubMed ID: 11106260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Dilley J; Reddy S; Ko D; Nguyen N; Rojas G; Working P; Yu DC
    Cancer Gene Ther; 2005 Aug; 12(8):715-22. PubMed ID: 15832172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
    Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
    Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
    Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
    Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription-targeted gene therapy for androgen-independent prostate cancer.
    Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
    Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer.
    Xie X; Zhao X; Liu Y; Zhang J; Matusik RJ; Slawin KM; Spencer DM
    Cancer Res; 2001 Sep; 61(18):6795-804. PubMed ID: 11559553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
    Latham JP; Searle PF; Mautner V; James ND
    Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
    Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
    Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
    Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
    Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity.
    Chen Y; DeWeese T; Dilley J; Zhang Y; Li Y; Ramesh N; Lee J; Pennathur-Das R; Radzyminski J; Wypych J; Brignetti D; Scott S; Stephens J; Karpf DB; Henderson DR; Yu DC
    Cancer Res; 2001 Jul; 61(14):5453-60. PubMed ID: 11454691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.